Research programme: p53 modulators - Actavalon
Alternative Names: p53 tumor suppressorLatest Information Update: 28 Sep 2022
At a glance
- Originator Actavalon
- Class Antineoplastics; Small molecules
- Mechanism of Action Tumour suppressor protein p53 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for research development in Cancer in USA
- 15 Aug 2018 Early research in Cancer in USA (unspecified route)